NCT07603713 LP-005 Periodontitis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook

Turn a newly registered trial into a decision-ready clinical landscape. This report examines NCT07603713 using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, with Drug & Asset MCP and Company & Deal Intelligence MCP used as the companion asset and sponsor enrichment workflow. Explore PatSnap MCP Servers to reproduce the research sequence inside an AI workflow.

MCP evidence snapshot: 23 July 2026. Trial records, recruitment status and projected dates can change after the snapshot and should be rechecked before operational decisions.

Why NCT07603713 is a hot trial to watch

Periodontitis is being segmented by mechanism, treatment setting, geography and endpoint architecture. NCT07603713 is notable because it evaluates LP-005 in a Phase 2 design sponsored by Longbio Pharma (Suzhou) Co., Ltd.. The main development question is whether the protocol can translate its rationale into a clinically interpretable and operationally credible readout.

Trial landscape snapshot

Protocol design and endpoint interpretation

This is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical study designed to evaluate the clinical efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of multiple local injections of different doses of LP-005 injection in patients with moderate-to-severe periodontitis, and to investigate changes in biomarker levels.

Allocation is Randomized, masking is Quadruple, and the intervention model is Parallel Assignment. Planned enrollment of [object Object] participants across China shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.

• Change from Baseline in Gingival Index (GI) (Day 43, Day 85, Day 127, and Day 169) — GI is measured using the Löe-Silness scale (range: 0-3), where higher scores indicate more severe gingival inflammation (worse outcome). Changes from baseline in gingival index (GI) scores are measured at Day 43, Day 85, Day 127, and Day 169 after the first administration of LP-005 injection.
• Change from Baseline in Bleeding Index (BI) (Day 43, Day 85, Day 127, and Day 169) — BI is measured using the Caton-Paton scale (range: 0-4), where higher scores indicate more severe gingival bleeding (worse outcome). Changes from baseline in BI scores are measured at Day 43, Day 85, Day 127, and Day 169 after the first administration of LP-005 injection.
• Change from Baseline in Probing Pocket Depth (PD) (Day 43, Day 85, Day 127, and Day 169) — Changes from baseline in probing pocket depth (PD) are measured at Day 43, Day 85, Day 127, and Day 169 after the first administration of LP-005 injection.
• Change from Baseline in Clinical Attachment Loss (AL) (Day 43, Day 85, and Day 127, Day 169) — Clinical AL is evaluated by standardized periodontal probing: after measuring probing depth, the probe tip is withdrawn along the root surface to identify the cemento-enamel junction (CEJ). The distance from the CEJ to the gingival margin (GM) is recorded. AL is calculated by subtracting this distance from the probing depth. A result of zero or an undetectable CEJ indicates no attachment loss. In cases of gingival re

Readout outlook and evidence gap

The current protocol points to [object Object] as the best available readout proxy. Because this is an active or newly posted study, a trial-specific result citation is not included until a normalized clinical-trial-result record becomes available. That gap is itself operationally important: teams should monitor first result indexing, conference abstracts, protocol amendments and changes to the primary-completion date.

Build a living trial monitor: connect to PatSnap MCP Servers and track recruitment, endpoint revisions, projected readouts and new result records without manually reconciling separate databases.

Asset and sponsor context

Drug & Asset MCP profile: LP-005 is indexed as Bispecific antibody, Fusion protein, with target C3b x C5, mechanism C3b inhibitors, C5 inhibitors, and global highest development status Phase 2.

Company & Deal Intelligence MCP profile: Longbio Pharma (Suzhou) Co., Ltd. is resolved to a normalized organization record in Suzhou, China. The organization workflow adds identity, location, portfolio and partnering context where available.

The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.

White space around this program

• Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
• Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
• Comparator relevance: evidence against the most decision-relevant contemporary standard of care.
• Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
• Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.

What to monitor next

Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter the probability of success before a headline data release.

Bottom line

NCT07603713 provides a focused lens on Periodontitis development. Its value will be determined by whether LP-005 can convert the current Phase 2 design into evidence that is clinically meaningful, operationally credible and differentiated from competing programs.

Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.